EL7.AI
StocksMedium•6 November 2026•
1 min read

Glenmark Q2 Net Profit Drops 57% Amid Legal Settlements

Key Facts

1Glenmark reported a consolidated net profit of ₹264 crore for Q2 FY27, a 57% year-on-year decline.
2Revenue decreased to ₹4,247 crore from ₹6,047 crore, with EBITDA margin contracting to 20.34% from 39.02%.

Glenmark Pharmaceuticals reported a consolidated net profit of ₹264 crore for the second quarter of fiscal year 2027, marking a 57% decline compared to the same period last year. According to scanx.trade, revenue decreased to ₹4,247 crore from ₹6,047 crore in the previous year, while the EBITDA margin contracted to 20.34% from 39.02%.

The decline was primarily driven by exceptional items including legal settlements in the United States, where Glenmark Pharmaceuticals Inc., USA reached an agreement with Humana, Inc. during the quarter ended September 30, 2026. These settlements, along with associated legal and regulatory costs totaling approximately ₹284 crore, impacted overall results despite growth in core business segments across India and Europe.